

# CELL BIOTECH

---

Probiotics & Microbiome company



## 2025 1Q Earnings Release

2025. 05.

As a note, it is suggested to use this material only as a reference, as it contains information and data that are subject to changes without prior notice due to the external audit process, and may cause the actual results to differ from those stated or implied in this material.

# 1q Earnings Summary

CELL BIOTECH

Revenue down 13.9% to KRW 11.2 billion, operating profit up 27.1% to KRW 1.4 billion

Domestic revenue down 17.7%, overseas revenue down 10.1%

Duolac brand sales down 2.8% to KRW 6.4 billion, OEM/ODM sales down 33.9% to KRW 3.5 billion, Raw material sales down 11.7% to KRW 1.4 billion

(unit : KRW 100 mil)


	2024 1q	% of revenue	2025 1q	% of revenue	YoY(%)
Revenue	130.4		112.3		-13.9
Domestic	64.9	49.8	53.4	47.6	-17.7
Overseas	65.5	50.2	58.9	52.4	-10.1
	2024 1q	Profit margin (%)	2025 1q	Profit margin (%)	YoY(%)
Operating Profit	10.7	8.2	13.6	12.1	27.1
Net Profit	32.6	25	20.7	18.4	-36.5

# Revenue trends


CELL BIOTECH

1q revenue KRW 12.2 billion, yoy -13.9%, qoq -7.6%

## Quarterly revenue



## Full year revenue




# Profit trends

CELL BIOTECH


1q operating profit KRW 1.4 billion, yoy +27.1%

Net Profit KRW +2.1 bil.

## Quarterly profit




## Full year profit



# Revenue breakdown

CELL BIOTECH

1q revenue of Duolac brand -2.8% to 6.4 KRW bil., OEM/ODM -33.9% to 3.5 KRW bil., and raw material -11.7% to 1.4 KRW bil.



## Microbiome R&D

- 1) Microbiome First-in-Class anticancer pipeline 'PP-P8' clinical phase 1 IND submitted (Mar 5, 2021)
- 2) Acquisition European patent of PP-P8 (Apr 1, 2021) (patent number EP3453718)
- 3) Acquired US patent for Probiotics drug delivery system (22. 12. 20)
- 4) P8 anticancer mechanism paper MOA (23.06.07)  
Anti-Cancer Roles of Probiotic-Derived P8 Protein in Colorectal Cancer Cell Line DLD-1, Int. J. Mol. Sci, 2023
- 5) Cellbiotech, Colorectal Cancer Drug Phase 1 Clinical Trial Plan Approved by Korea MFDS  
(Mar 20, 2024)
- 6) Cellbiotech starts phase 1 of microbiome colorectal cancer drug 'PP-P8'

<https://www.hankyung.com/article/202502194939i>

## No. 1 in global export for 11 consecutive years

- 1) Cellbiotech's probiotics 'DUOLAC' ranked No. 1 in the world for 11 consecutive years



Consumers in Denmark purchasing Duolac. Provided by Cell Biotech

<https://biz.heraldcorp.com/article/3452182>

## FDA GRAS World's Most Listed

1) Cellbiotech "11 types of lactic acid bacteria secured FDA GRAS certification... The World's Largest Holdings"



<https://www.hankyung.com/article/202402222016i>

2) Cellbiotech, Probiotics Leading... Global Leap



<https://www.dailypharm.com/Users/News/NewsView.html?ID=309331&REFERER=NP>

# Consolidated Financial Summary

CELL BIOTECH

## Income statement

(unit : KRW 100 mil., %)

	2024 1q		2025 1q	
	Amount	Ratio	Amount	Ratio
Revenue	130.4	100	112.3	100
Gross profit	93.4	71.6	79.8	71.1
SG&A expenses	82.7	63.4	66.2	58.9
Operating profit	10.7	8.2	13.6	12.1
Consolidated net income	32.6	25.0	20.7	18.4

## Statement of financial position

(unit : KRW 100 mil., %)

	2024 .12	2025 .1Q
Assets	1,304	1,326
Current Assets	972	1,001
Non current Assets	332	325
Liabilities	62	93
Current Liabilities	59	90
Non current Liabilities	3	3
Shareholder's Equity	1,242	1,233